Catalyst Wire Dossier Catalyst Wire Dossier

eribulin mesilate

eribulin mesilate · Eisai Inc.
Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for eribulin mesilate, covering 2022-06-28 to 2022-06-28. Get the full timeline:

Most recent: Clinical Trial Update: Study Evaluating the Safety and Efficacy of Eribulin Mesilate in Combination With Irinotecan Hydrochloride in Children With Refractory or Recurrent Solid Tumors [Phase 1, Phase 2]

See pricing